Overview

Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-06-15

Target enrollment:

Participant gender:

Summary

This study is a multicenter, single-arm, phase II exploratory study, aims to evaluate the efficacy and safety of metronomic capecitabine with camrelizumab and apatinib mesylate in advanced pancreatic cancer after the failure of first-line treatment.

Phase:

PHASE2

Details

Lead Sponsor:

Zhejiang University

Treatments:

apatinib
camrelizumab